Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Summary: Haematological toxicities and thromboembolic (TE) events are common complications of myeloma therapy. TE risk may be elevated with combination regimens, notably thalidomide/lenalidomide plus high‐dose dexamethasone; concomitant erythropoietin appears to further increase the risk with lenalidomide–dexamethasone. We characterised thrombocytopenia and neutropenia in the phase 3 APEX (Assessment of Proteasome Inhibition for Extending Remissions) study of bortezomib versus high‐dose dexamethasone in relapsed myeloma, and calculated the incidences of deep‐vein thrombosis (DVT)/pulmonary embolism (PE) with: bortezomib or dexamethasone ± erythropoietin in APEX; bortezomib ± dexamethasone ± erythropoietin in two phase 2 studies of relapsed/refractory myeloma. Bortezomib‐associated thrombocytopenia and neutropenia were transient, predictable and manageable; mean platelet and neutrophil counts followed a cyclical pattern, and improved over the treatment course. Grade 3/4 thrombocytopenia incidence was higher with bortezomib versus dexamethasone (26%/4% vs. 5%/1%), but significant bleeding events were comparable (4% vs. 5%). DVT/PE incidence was low (≤3·1%) in all analyses; addition of dexamethasone/erythropoietin did not affect TE risk. In APEX, TE risk appeared lower with bortezomib versus dexamethasone. Bortezomib caused transient and cyclical thrombocytopenia and was not associated with elevated TE risk, alone or with dexamethasone ± erythropoietin. Preliminary data suggest bortezomib may reduce the thrombogenic potential of combination regimens via inhibition of platelet function or other mechanism‐specific effects on coagulation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632 · cited 3×
“Full details of APEX, SUMMIT and CREST have been published previously (Richardson et al, 2003, 2005; Jagannath et al, 2004).”
MethodSelf-citationLenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450 · cited 1×
“…in the front-line and relapsed settings (Osman et al, 2001; Zangari et al, 2001, 2002; Rajkumar et al, 2002, 2006; Urbauer et al, 2002; Weber et al, 2003, 2007; Barlogie et al, 2006; Hussein et al, 2006; Knight et al, 2006; Niesvizky et al, 2006, 2008; Palumbo et al, 2006; Dimopoulos et al, 2007).”
BackgroundSelf-citationLenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233 · cited 1×
“…both in the front-line and relapsed settings (Osman et al, 2001; Zangari et al, 2001, 2002; Rajkumar et al, 2002, 2006; Urbauer et al, 2002; Weber et al, 2003, 2007; Barlogie et al, 2006; Hussein et al, 2006; Knight et al, 2006; Niesvizky et al, 2006, 2008; Palumbo et al, 2006;…”
BackgroundSelf-citationRajkumar, S. V., Blood, E., Vesole, D., Fonseca, R., & Greipp, P. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.0221 · Cited by 865 · cited 1×
“…Journal of Haematology, 143, 222–229 225 dexamethasone, both in the front-line and relapsed settings (Osman et al, 2001; Zangari et al, 2001, 2002; Rajkumar et al, 2002, 2006; Urbauer et al, 2002; Weber et al, 2003, 2007; Barlogie et al, 2006; Hussein et al, 2006; Knight et al, 2006;…”
BackgroundSelf-citationCombination Therapy With Thalidomide Plus Dexamethasone for Newly Diagnosed Myeloma
Rajkumar, S. V., Hayman, S., Gertz, M. A., Dispenzieri, A., Lacy, M. Q., Greipp, P. R., Geyer, S., Iturria, N., Fonseca, R., Lust, J. A., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.02.116 · Cited by 512 · cited 1×
“…Journal of Haematology, 143, 222–229 225 dexamethasone, both in the front-line and relapsed settings (Osman et al, 2001; Zangari et al, 2001, 2002; Rajkumar et al, 2002, 2006; Urbauer et al, 2002; Weber et al, 2003, 2007; Barlogie et al, 2006; Hussein et al, 2006; Knight et al, 2006;…”
BackgroundSelf-citation
Cited by
Palumbo, A., & Anderson, K. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011442 · Cited by 2,326
Self-citationRichardson, P. G., Weller, E., Lonial, S., Jakubowiak, A. J., Jagannath, S., Raje, N. S., Avigan, D. E., Xie, W., Ghobrial, I. M., Schlossman, R. L., et al. (2010) · Blood · doi:10.1182/blood-2010-02-268862 · Cited by 861
Self-citationBortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma
Robak, T., Huang, H., Jin, J., Zhu, J., Liu, T., Samoilova, O., Pylypenko, H., Verhoef, G., Siritanaratkul, N., Osmanov, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412096 · Cited by 386
The proteasome and proteasome inhibitors in multiple myeloma
Gandolfi, S., Laubach, J. P., Hideshima, T., Chauhan, D., Anderson, K. C., & Richardson, P. G. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9707-8 · Cited by 340
Self-citationRichardson, P. G., Weller, E., Jagannath, S., Avigan, D. E., Alsina, M., Schlossman, R. L., Mazumder, A., Munshi, N. C., Ghobrial, I. M., Doss, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.2679 · Cited by 162
“thromboprophylaxis may have reduced the risk of this complication,(25,26) and bortezomib may have additionally abrogated it.(23,27-29)”
BackgroundSelf-citation
Metadata
- Authors
- Lonial, S., Richardson, P. G., San Miguel, J., Sonneveld, P., Schuster, M. W., Bladé, J., Cavenagh, J., Rajkumar, S. V., Jakubowiak, A. J., Esseltine, D., Anderson, K. C., & Harousseau, J.
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2008-09-24
- Volume
- 143
- Issue
- 2
- Pages
- 222-229
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W2165065963
- Cited by
- 94
- References
- 5
- FWCI
- 8.01
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma. https://app.cochat.ai/papers/10.1111/j.1365-2141.2008.07321.x
- The paper
- Lonial, S., Richardson, P. G., San Miguel, J., Sonneveld, P., Schuster, M. W., Bladé, J., Cavenagh, J., Rajkumar, S. V., Jakubowiak, A. J., Esseltine, D., Anderson, K. C., & Harousseau, J. (2008). Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma. British Journal of Haematology. https://doi.org/10.1111/j.1365-2141.2008.07321.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.